Clinical Trial for Prostate Cancer - Full Text View

Clinical Trial for Prostate Cancer

This study has been completed.

Sponsored by:	Oakwood Laboratories, LLC
Information provided by:	Oakwood Laboratories, LLC
ClinicalTrials.gov Identifier:	NCT00076531

Purpose

Phase III trial using an injectable for treatment of prostate cancer.

Condition	Intervention	Phase
Prostate Cancer	Drug: Leuprolide Acetate for Injectable Suspension 22.5 mg	Phase III

MedlinePlus related topics:

Cancer Prostate Cancer

Drug Information available for:

Leuprolide acetate Leuprolide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Safety/Efficacy Study

Further study details as provided by Oakwood Laboratories, LLC:

Study Start Date:	December 2003
Primary Completion Date:	November 2004 (Final data collection date for primary outcome measure)

Eligibility

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00076531

Sponsors and Collaborators

Oakwood Laboratories, LLC

Investigators


Study Chair:	James A. Page, M.D.	Oakwood Laboratories, LLC

More Information

Oakwood (sponsor) site This link exits the ClinicalTrials.gov site

Study ID Numbers:	OL-007
First Received:	January 26, 2004
Last Updated:	January 24, 2008
ClinicalTrials.gov Identifier:	NCT00076531
Health Authority:	United States: Food and Drug Administration

Keywords provided by Oakwood Laboratories, LLC:

Prostate

Cancer

PSA

Leuprolide

Study placed in the following topic categories:

Prostatic Diseases

Genital Neoplasms, Male

Leuprolide

Urogenital Neoplasms

Genital Diseases, Male

Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

Antineoplastic Agents, Hormonal

Antineoplastic Agents

Therapeutic Uses

Fertility Agents, Female

Physiological Effects of Drugs

Fertility Agents

Reproductive Control Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008